A comparison of the lipolytic and anticoagulative properties of heparin and pentosan polysulphate in the thoroughbred horse.
The aim of the study was to develop a model for the pre-exercise elevation of plasma free fatty acids in the horse, with a view to its future use in investigations of fat metabolism during exercise. A comparison of the lipase releasing and anticoagulative effects of heparin and a related substance pentosan polysulphate was investigated. Furthermore, the ability of heparin and pentosan polysulphate to affect an increase in plasma free fatty acid concentration, when co-administered with-a triglyceride emulsion, was quantified. Doses of 0.39 and 1.3 mg kg-1 body wt of heparin and pentosan polysulphate respectively, administered intravenously, resulted in a significant increase in plasma total lipase activity (P < 0.001). There was, however, no significant difference in plasma lipase activity between treatments. Heparin resulted in a mean 14 +/- 6.5-fold increase in activated partial thromboplastin time compared with a mean 1.6 +/- 0.1-fold increase with pentosan polysulphate. Both heparin and pentosan polysulphate when coadministered with a triglyceride emulsion (lverlip 20) resulted in a significant increase in plasma free fatty acid concentration (P < 0.001), although there was no significant difference between treatments. Thus, whereas a higher dose of pentosan polysulphate elicited a comparable lipolytic effect to heparin, including significant elevation of plasma free fatty acids, this was associated with a much reduced effect upon clotting function. Pentosan polysulphate, therefore, represents a suitable alternative to heparin for the elevation of plasma free fatty acids before exercise when used in conjunction with a triglyceride emulsion.
Orme
C E
CE
Physiology Unit, Equine Centre, Animal Health Trust, Suffolk, UK.
Harris
R C
RC
D000822:Animal Husbandry; D000818:Animals; D000925:Anticoagulants / Q000494:pharmacology*; D001777:Blood Coagulation / Q000187:drug effects; D005230:Fatty Acids, Nonesterified / Q000097:blood; D005343:Fibrinolytic Agents / Q000494:pharmacology*; D006493:Heparin / Q000494:pharmacology*; D006736:Horses / Q000097:blood*; D008049:Lipase / Q000097:blood; D008066:Lipolysis; D010314:Partial Thromboplastin Time; D010426:Pentosan Sulfuric Polyester / Q000494:pharmacology*; D014280:Triglycerides / Q000097:blood
D000925:Anticoagulants; D005230:Fatty Acids, Nonesterified; D005343:Fibrinolytic Agents; D014280:Triglycerides; D010426:Pentosan Sulfuric Polyester; D006493:Heparin; D008049:Lipase